Clinical Trial Update: A Study of the Combination of Pemetrexed and Irinotecan Every Two Weeks in Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating pemetrexed plus irinotecan every two weeks in metastatic colorectal cancer; results were posted for this completed trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Camptosar (irinotecan)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Metastatic Colorectal Cancer | Phase 2 | Status: COMPLETED | Results posted: 2009-06-15